CARDIONOVUM GmbH
Marcello Gramola is an experienced leader in the cardiology sector, currently serving as the Director of Cardiology at CARDIONOVUM GmbH since December 2023. Prior roles include Sales & Marketing Director at CARDIVA, where responsibilities spanned from June 2020 to December 2023, and Area Business Manager Europe and Country Manager at iVascular between February 2017 and June 2020. Marcello has held significant positions at Direct Flow Medical®, Hexacath, St Jude Medical Italy, and Boston Scientific/Guidant Italy, with a strong focus on sales, marketing strategies, P&L management, and team leadership throughout a distinguished career beginning in 1997.
This person is not in any offices
CARDIONOVUM GmbH
CARDIONOVUM, a medical technology company based in Bonn, Germany, develops and commercializes innovative medical devices such as the new generation of DCB and drug-eluting stents for the treatment of coronary and peripheral artery disease. The company’s pioneering range of DCBs is based on the SAFEPAX® paclitaxel coating matrix which has the lowest wash-off rates on the market. The company’s strong commitment to clinical research ensures a continually deepening and expanding evidence-base in support of the clinical benefits of our products. Pioneers in medical devices. The worldwide first CE-approved DCB. With the first DCB market introduction, CARDIONOVUM contributed significantly to the establishment of a new medical device therapy to treat coronary and peripheral artery disease effectively. CARDIONOVUM consists of R & D staff, with the longest and most profound experience, in developing clinically advanced DCB and DES cardiovascular devices. “Live Deserves the Best”